Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder

PURPOSE: Long-term persistence with pharmacotherapy for overactive bladder (OAB) requires a drug with an early onset of action and good efficacy and tolerability profile. Although antimuscarinics improve OAB symptoms within 1–2 weeks of initiating treatment, adherence after 3 months is relatively po...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:World J Urol
Main Authors: Chapple, Christopher R., Nitti, Victor W., Khullar, Vik, Wyndaele, Jean Jacques, Herschorn, Sender, van Kerrebroeck, Philip, Blauwet, Mary Beth, Siddiqui, Emad
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2014
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4236626/
https://ncbi.nlm.nih.gov/pubmed/24458878
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00345-014-1244-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados